On Jun. 2, 2020, Agenus announced the FDA’s clearance of AgenTus’ IND application for an allogeneic iNKT therapy. AgenT-797 had been submitted. A clinical trial for the treatment of patients with COVID-19 was expected to commence in the near-term. Agenus previously reported the FDA clearance of the IND for the use of allogeneic iNKTs for patients with cancer.